|
1
|
van der Woude D and van der Helm-van Mil
AHM: Update on the epidemiology, risk factors, and disease outcomes
of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 32:174–187.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Londoño J, Peláez Ballestas I, Cuervo F,
Angarita A, Giraldo R, Rueda JC, Ballesterosa JG, Baquero R, Forero
E, Cardiel M, et al: Prevalence of rheumatic disease in Colombia
according to the Colombian Rheumatology Association (COPCORD)
strategy. Prevalence study of rheumatic disease in Colombian
population older than 18 years. Rev Colombiana de Reumatol.
25:245–256. 2018.
|
|
3
|
Anderson J, Caplan L, Yazdany J, Robbins
ML, Neogi T, Michaud K, Saag KG, O'Dell JR and Kazi S: Rheumatoid
arthritis disease activity measures: American College of
Rheumatology recommendations for use in clinical practice.
Arthritis Care Res (Hoboken). 64:640–647. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Smolen JS, Landewé R, Breedveld FC, Buch
M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam
J, et al: EULAR recommendations for the management of rheumatoid
arthritis with synthetic and biological disease-modifying
antirheumatic drugs: 2013 update. Ann Rheum Dis. 73:492–509.
2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Singh JA, Furst DE, Bharat A, Curtis JR,
Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL,
Beukelman T, et al: 2012 update of the 2008 American College of
Rheumatology recommendations for the use of disease-modifying
antirheumatic drugs and biologic agents in the treatment of
rheumatoid arthritis. Arthritis Care Res (Hoboken). 64:625–639.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
O'Dell JR, Leff R, Paulsen G, Haire C,
Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, et
al: Treatment of rheumatoid arthritis with methotrexate and
hydroxychloroquine, methotrexate and sulfasalazine, or a
combination of the three medications: Results of a two-year,
randomized, double-blind, placebo-controlled trial. Arthritis
Rheum. 46:1164–1170. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aletaha D and Smolen JS: Diagnosis and
management of rheumatoid Arthritis: A review. JAMA. 320:1360–1372.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Emery P, Breedveld FC, Hall S, Durez P,
Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS and
Freundlich B: Comparison of methotrexate monotherapy with a
combination of methotrexate and etanercept in active, early,
moderate to severe rheumatoid arthritis (COMET): A randomised,
double-blind, parallel treatment trial. Lancet. 372:375–382.
2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Treon SP and Chabner BA: Concepts in use
of high-dose methotrexate therapy. Clin Chem. 42:1322–1329.
1996.PubMed/NCBI
|
|
10
|
Verhoeven AC, Boers M and Tugwell P:
Combination therapy in rheumatoid arthritis: Updated systematic
review. Br J Rheumatol. 37:612–619. 1998.PubMed/NCBI View Article : Google Scholar
|
|
11
|
van Ede AE, Laan RF, Blom HJ, De Abreu RA
and van de Putte LB: Methotrexate in rheumatoid arthritis: An
update with focus on mechanisms involved in toxicity. Semin
Arthritis Rheum. 27:277–292. 1998.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grim J, Chládek J and Martínková J:
Pharmacokinetics and pharmacodynamics of methotrexate in
non-neoplastic diseases. Clin Pharmacokinet. 42:139–151.
2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Edno L, Bressolle F, Gomeni R, Bologna C,
Sany J and Combe B: Total and free methotrexate pharmacokinetics in
rheumatoid arthritis patients. Ther Drug Monit. 18:128–134.
1996.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cronstein BN: The mechanism of action of
methotrexate. Rheum Dis Clin North Am. 23:739–755. 1997.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Blits M, Jansen G, Assaraf YG, van de Wiel
MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE,
Wolbink GJ, Vosslamber S and Verweij CL: Methotrexate normalizes
up-regulated folate pathway genes in rheumatoid arthritis.
Arthritis Rheum. 65:2791–2802. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Umićević Mirkov M and Coenen MJ:
Pharmacogenetics of disease-modifying antirheumatic drugs in
rheumatoid arthritis: Towards personalized medicine.
Pharmacogenomics. 14:425–444. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhu H, Deng FY, Mo XB, Qiu YH and Lei SF:
Pharmacogenetics and pharmacogenomics for rheumatoid arthritis
responsiveness to methotrexate treatment: The 2013 update.
Pharmacogenomics. 15:551–566. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Romão VC, Lima A, Bernardes M, Canhão H
and Fonseca JE: Three decades of low-dose methotrexate in
rheumatoid arthritis: Can we predict toxicity? Immunol Res.
60:289–310. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Boughrara W, Benzaoui A, Aberkane M,
Moghtit FZ, Dorgham S, Lardjam-Hetraf AS, Ouhaibi-Djellouli H,
Teixeira EP and Boudjema A: No correlation between MTHFR c.677 C
> T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T
polymorphisms and methotrexate therapeutic outcome of rheumatoid
arthritis in West Algerian population. Inflamm Res. 66:505–513.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ranganathan P: An update on methotrexate
pharmacogenetics in rheumatoid arthritis. Pharmacogenomics.
9:439–451. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lee YH and Bae SC: Association of the ATIC
347 C/G polymorphism with responsiveness to and toxicity of
methotrexate in rheumatoid arthritis: A meta-analysis. Rheumatol
Int. 36:1591–1599. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Restrepo LF, Giraldo R, Londoño J, Pinzón
C, Cortes A, Ballesteros G and Santos MA: Farmacogenética del
metotrexato en artritis reumatoide. Revisión sistemática
harmacogenetics of methotrexate in rheumatoid arthritis: A
systematic review. Revista Colombiana de Reumatología. 23:102–114.
2016.
|
|
23
|
Aletaha D, Neogi T, Silman AJ, Funovits J,
Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP,
Cohen MD, et al: 2010 rheumatoid arthritis classification criteria:
An American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Ann Rheum Dis. 69:1580–1588.
2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Santos AM, Saldarriaga EL, Giraldo-Bustos
R, Ballesteros-Muñoz JG, Rueda JC, Cuervo FM, Angarita JI, Vásquez
AY, Arias-Correal S, González CA, et al: Dickkopf 1 protein
circulating levels as a possible biomarker of functional disability
and chronic damage in patients with rheumatoid arthritis. Clin
Rheumatol. 37:795–801. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Muñoz JGB, Giraldo RB, Santos AM,
Bello-Gualteros JM, Rueda JC, Saldarriaga EL, Angarita JI,
Arias-Correal S, Vasquez AY and Londono J: Correlation between
rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a
cohort of Colombian patients with rheumatoid arthritis. Clin
Rheumatol. 36:1143–1148. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
World Medical Association: World Medical
Association Declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA 310: 2191-2194, 2013.
|
|
27
|
Urano W, Taniguchi A, Yamanaka H, Tanaka
E, Nakajima H, Matsuda Y, Akama H, Kitamura Y and Kamatani N:
Polymorphisms in the methylenetetrahydrofolate reductase gene were
associated with both the efficacy and the toxicity of methotrexate
used for the treatment of rheumatoid arthritis, as evidenced by
single locus and haplotype analyses. Pharmacogenetics. 12:183–190.
2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Xiao H, Xu J, Zhou X, Stankovich J, Pan F,
Zhang Z, Xu S, Lian L and Ding C: Associations between the genetic
polymorphisms of MTHFR and outcomes of methotrexate treatment in
rheumatoid arthritis. Clin Exp Rheumatol. 28:728–733.
2010.PubMed/NCBI
|
|
29
|
Romero-Sánchez C, Gómez-Gutierrez A, Gómez
PE, Casas-Gomez MC and Briceño I: C677T (RS1801133) MTHFR gene
polymorphism frequency in a colombian population. Colomb Med
(Cali). 46:75–79. 2015.PubMed/NCBI
|
|
30
|
Mena JP, Salazar-Páramo M, González-López
L, Gámez-Nava JI, Sandoval-Ramirez L, Sánchez JD, Figuera LE,
Muñoz-Valle FJ, Vazquez del Mercado M and Dávalos IP: Polymorphisms
C677T and A1298C in the MTHFR gene in Mexican patients with
rheumatoid arthritis treated with methotrexate: Implication with
elevation of transaminases. Pharmacogenomics J. 11:287–291.
2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wessels JA, de Vries-Bouwstra JK, Heijmans
BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van
Zeben D, Breedveld FC, Dijkmans BA, et al: Efficacy and toxicity of
methotrexate in early rheumatoid arthritis are associated with
single-nucleotide polymorphisms in genes coding for folate pathway
enzymes. Arthritis Rheum. 54:1087–1095. 2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zajc Avramovič M, Dolžan V, Toplak N,
Accetto M, Lusa L and Avčin T: Relationship between polymorphisms
in methotrexate pathway genes and outcome of methotrexate treatment
in a cohort of 119 patients with Juvenile idiopathic arthritis. J
Rheumatol. 44:1216–1223. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dervieux T, Furst D, Lein DO, Capps R,
Smith K, Walsh M and Kremer J: Polyglutamation of methotrexate with
common polymorphisms in reduced folate carrier, aminoimidazole
carboxamide ribonucleotide transformylase, and thymidylate synthase
are associated with methotrexate effects in rheumatoid arthritis.
Arthritis Rheum. 50:2766–2774. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Grabar PB, Rojko S, Logar D and Dolzan V:
Genetic determinants of methotrexate treatment in rheumatoid
arthritis patients: A study of polymorphisms in the adenosine
pathway. Ann Rheum Dis. 69:931–932. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Salazar J, Moya P, Altés A, Díaz-Torné C,
Casademont J, Cerdà-Gabaroi D, Corominas H and Baiget M:
Polymorphisms in genes involved in the mechanism of action of
methotrexate: Are they associated with outcome in rheumatoid
arthritis patients? Pharmacogenomics. 15:1079–1090. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Owen SA, Lunt M, Bowes J, Hider SL, Bruce
IN, Thomson W and Barton A: MTHFR gene polymorphisms and outcome of
methotrexate treatment in patients with rheumatoid arthritis:
Analysis of key polymorphisms and meta-analysis of C677T and A1298C
polymorphisms. Pharmacogenomics J. 13:137–147. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fan AZ, Yesupriya A, Chang MH, House M,
Fang J, Ned R, Hayes D, Dowling NF and Mokdad AH: Gene
polymorphisms in association with emerging cardiovascular risk
markers in adult women. BMC Med Genet. 11(6)2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Palomino-Morales R, Gonzalez-Juanatey C,
Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA,
Fernandez-Gutierrez B, Llorca J, Martin J and Gonzalez-Gay MA:
A1298C polymorphism in the MTHFR gene predisposes to cardiovascular
risk in rheumatoid arthritis. Arthritis Res Ther.
12(R71)2010.PubMed/NCBI View
Article : Google Scholar
|
